Turn Therapeutics Inc. 8-K

What Happened
Turn Therapeutics Inc. (TTRX) announced on March 23, 2026 that it entered a Loan and Security Agreement with Avenue Venture Opportunities Fund II, L.P. as agent and lender. The facility makes up to $25.0 million available in term loans (with an immediate funded Tranche 1 of $7.0 million), plus a possible discretionary additional tranche. The loans are secured by substantially all of the Company’s assets, bear interest at the greater of (prime + 5.50%) or 12.25%, and mature on October 1, 2029. In connection with the financing the Company issued an equity grant valued at $1.2 million to the lender.

Key Details

• Amounts & timing: $25.0M total available (Tranche 1 = $7.0M funded at closing Mar 23, 2026; Tranche 2 = up to $8.0M available Sep 1, 2026–Mar 31, 2027 subject to milestones; Discretionary Tranche 3 = up to $10.0M available Jan 1, 2027–Jun 30, 2028 subject to milestones and lender approval).
• Cost & fees: Interest = greater of prime + 5.50% and 12.25%; commitment fee $150,000 (with $50,000 previously paid); final fee = 3.75% of aggregate funded amount due at maturity or full prepayment; tiered prepayment fees (3%/2%/1% depending on timing).
• Security & covenants: Loans are secured by a lien on substantially all assets, including intellectual property; customary covenants and default remedies apply. There is no minimum cash requirement or other financial covenant.
• Equity/dilution features: Company issued $1.2M in common stock to the lender (VWAP-based). Lender has a conversion option to convert up to $2.0M (up to $3.0M if Tranche 2 funded) of outstanding principal into shares at 80% of the closing stock price at exercise, and a participation right to invest up to $1.0M in future equity financings (subject to limits).

Why It Matters
This financing provides immediate liquidity (a $7.0M cash infusion now and potential access to more capital tied to milestones), which can help fund operations and development without an immediate equity raise. However, the facility is secured by the company’s assets and includes equity-linked features (a $1.2M share grant and a conversion option) that can dilute existing shareholders if exercised. The interest-rate floor (12.25% effective minimum) plus fees and prepayment penalties make this a relatively costly form of financing compared with typical equity raises. Investors should weigh the near-term cash benefit and lack of financial covenants against potential dilution and the company’s reduced asset flexibility due to the security interest.